Promising New HIV-Prevention Drug Is Hard to Find Where It's Most Needed, in Places Like Uganda
The generic could widen access to a twice-yearly HIV prevention shot as clinics in Uganda report doses running out within days.
- On Monday, the U.S. Food and Drug Administration tentatively approved a generic version of lenacapavir, aiming to lower costs in 120 low-income countries to roughly $40 annually, far below the $28,218 U.S. list price.
- Shortages persist in Uganda, particularly in Mbarara, where the HIV rate is 10%, double the national average, driven largely by transactional sexual encounters.
- Patients like Lisa Mutoni and Julius Bampe face frequent supply gaps, with Mutoni reporting "it's not available. They tell me that it is finished" when seeking treatment at local facilities.
- The Global Fund aims to reach 3 million people by the end of 2028, though expert Andrew Hill, a senior visiting research fellow at the University of Liverpool, warns that "we need to be getting to the millions pretty soon."
- Doctors Without Borders urges Gilead Sciences to expand direct access, arguing that the company's claim to end the HIV epidemic "for everyone, everywhere" contradicts its current actions.
26 Articles
26 Articles
GazetteXtra
A promising new drug could turn the tide against HIV. But it's hard to find where it's needed most
Experts say that a promising drug that offers complete protection against HIV and requires only two shots a year isn't getting to enough people. Demand for lenacapavir is far outstripping supply in Uganda, other parts of Africa and all over…
My Mother Lode
Promising new HIV-prevention drug is hard to find where it’s most needed, in places like Uganda
Experts say that a promising drug that offers complete protection against HIV and requires only two shots a year isn't getting to enough people. Demand for lenacapavir is far outstripping supply in Uganda, other parts of Africa and all over the world. U.S. regulators on Monday approved a generic version for sale in low-income countries. That may help increase access in the coming months. But critics are calling on the drug's maker Gilead Science…
New HIV Prevention Drug Remains Scarce in Uganda and Other High-Need Countries
Internewscast Internewscast MBARARA – In Mbarara’s red-light district, a part of this western Ugandan… This Post: New HIV Prevention Drug Remains Scarce in Uganda and Other High-Need Countries first appeared on Internewscast
Promising new HIV-prevention drug is hard to find where it's most
MBARARA, Uganda (AP) — In the red light district in Mbarara, a city in western Uganda known in part for sex tourism, a sex worker named Lisa Mutoni insists on using condoms when men enter her room,
Promising new HIV-prevention drug is hard to find where it’s most needed, in places like Uganda – WTOP News
MBARARA, Uganda (AP) — In the red light district in Mbarara, a city in western Uganda known in part for sex tourism, a sex worker named Lisa Mutoni insists on using condoms when men enter her room, to protect her against HIV and other infections. The problem: Some try to remove or tear the condom...
Coverage Details
Bias Distribution
- 58% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
